Bulk anti-Human Hepsin antibody (2D5-1.9)

Target: Hepsin.

Clone: 2D5-1.9.

Specificity: Clone 2D5 recognizes Human hepsin. It binds to a separate epitope than clone 3H10.1. These clones do not interfere with one another.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Antigen Distribution: Hepsin is expressed on the surface of epithelial cells including the liver, kidney, prostate, and thyroid in human tissues.

Background: Hepsin is a type II transmembrane serine protease (TTSP) expressed on the surface of epithelial cells including the liver, kidney, prostate, and thyroid in human tissues. The physiological function of hepsin is unclear, although, In vitro studies have shown that hepsin activates blood clotting factors VII, XII, and IX, pro-urokinase (pro-uPA), and pro-hepatocyte growth factor (pro-HGF). The over-expression of hepsin has been implicated in several types of cancer, especially ovarian and prostate, which makes it an attractive diagnostic marker for cancers. Most notably, hepsin has been identified as one of the most highly induced genes in prostate cancer, and this over-expression is correlated with the cancer progression and metastasis. Furthermore anti-hepsin antibodies have been shown to inhibit the invasion of human prostate cancer cells.6.

Immunogen: Human hepsin protein.

Concentration: 1.0 – 5.0 mg/ml.

Formulation: This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and azide free.

Purity: >98% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Aggregation: Aggregation level ≤ 1%.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.